Provided by Tiger Fintech (Singapore) Pte. Ltd.

NeuroPace Inc.

11.79
+0.10000.86%
Post-market: 12.000.2100+1.78%18:26 EDT
Volume:100.60K
Turnover:1.18M
Market Cap:383.88M
PE:-12.65
High:11.96
Open:11.69
Low:11.46
Close:11.69
Loading ...

Cantor Fitzgerald Sticks to Their Buy Rating for NeuroPace (NPCE)

TIPRANKS
·
29 Jan

NeuroPace price target raised to $19 from $18 at Cantor Fitzgerald

TIPRANKS
·
29 Jan

NeuroPace Expects 2025 Revenue Growth

MT Newswires Live
·
29 Jan

NeuroPace Projects 2025 Growth and Product Enhancements

TIPRANKS
·
29 Jan

Neuropace, Inc. Outlook FY Gross Margin 73-75%

THOMSON REUTERS
·
29 Jan

Neuropace Inc: Three-Year Targets of 20% Revenue Cagr and Achievement of Cash Flow Breakeven

THOMSON REUTERS
·
29 Jan

Neuropace Issues 2025 Financial Guidance Targets

THOMSON REUTERS
·
29 Jan

NeuroPace Issues 2025 Financial Guidance Targets

GlobeNewswire
·
29 Jan

Lake Street Remains a Buy on NeuroPace (NPCE)

TIPRANKS
·
24 Jan

NeuroPace, Inc. (NASDAQ:NPCE) Looks Just Right With A 26% Price Jump

Simply Wall St.
·
24 Jan

NeuroPace (NPCE) Soars 9.1%: Is Further Upside Left in the Stock?

Zacks
·
22 Jan

Neuropace Inc : UBS Initiates Coverage With Buy Rating; Target Price $17

THOMSON REUTERS
·
21 Jan

NeuroPace initiated with a Buy at UBS

TIPRANKS
·
21 Jan

NeuroPace to Present at J.P. Morgan Healthcare Conference

TIPRANKS
·
16 Jan

Promising Outlook for NeuroPace: Revenue Beats, Clinical Progress, and Growth Catalysts

TIPRANKS
·
13 Jan

Analysts Offer Insights on Healthcare Companies: NeuroPace (NPCE), Tecan Group AG (OtherTCHBF) and Avidity Biosciences (RNA)

TIPRANKS
·
09 Jan

NeuroPace Sees Rise in 4Q, Full-Year Sales

Dow Jones
·
09 Jan

NeuroPace Strengthens Board and Reports Strong 2024 Results

TIPRANKS
·
09 Jan

NeuroPace Preliminary Q4 Revenue Increases; Shares Rise After Hours

MT Newswires Live
·
09 Jan

Neuropace Inc - Preliminary Q4 2024 Revenue Expected Between $21.0 Mln and $21.5 Mln

THOMSON REUTERS
·
09 Jan